Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.32 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2347781 | 0.77 | MAOA (0.30) | MAOAMAOB | |
| SCHEMBL14591143 | 0.77 | PARP1 (0.36) | TSHRMAOAMAOBHTR2CCA1 | |
| SCHEMBL27888014 | 0.73 | — | — | |
| SCHEMBL29471383 | 0.70 | — | — | |
| SCHEMBL59871 | 0.70 | — | — | |
| Ammonia Solution, Strong SCHEMBL23320033 | 0.68 | MAOA (0.40) | TSHRMAOAMAOBHTR2CCA1 | |
| SCHEMBL27721343 | 0.68 | — | — | |
| SCHEMBL16439994 | 0.68 | — | — | |
| SCHEMBL27422507 | 0.66 | PNMT (0.35) | HTR2CPARP1 | |
| SCHEMBL2075437 | 0.66 | MAOA (0.39) | TSHRMAOAMAOBHTR2CCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 259 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160046574-A1 | SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-18 | — | — | US | claimed |
| US-20140038943-A1 | SEROTONIN RECEPTOR MODULATOR | JANSSEN PHARMACEUTICA NV (US) | 2014-02-06 | — | — | US | claimed |
| US-8642583-B2 | Serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-04 | — | — | US | claimed |
| US-8283357-B2 | Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-10-09 | — | — | US | claimed |
| EP-2440517-A2 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-04-18 | — | — | EP | claimed |
| US-8039455-B2 | Macrocyclic compounds useful as BACE inhibitors | NOVARTIS AG (CH) | 2011-10-18 | — | — | US | claimed |
| US-8008250-B2 | 1-Hydroxy-2-(3-isopropyl-benzylamino)-ethyl]-9,10-dimethyl-2-oxa-9,12-diaza-bicyclo[13.3.1]nonadeca-1(19),15,17-triene-8,11-dione; secretase inhibitor; neurological, vascular disorders, beta-amyloid generation/aggregation; Alzheimer's disease, Down's Syndrome, cognitive impairment, amyloid neuropathies | NOVARTIS AG (CH) | 2011-08-30 | — | — | US | claimed |
| US-20110207714-A1 | SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-08-25 | — | — | US | claimed |
| WO-2010144378-A2 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD COLORADO, INC. (US) | 2010-12-16 | — | — | WO | claimed |
| US-20100311794-A1 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-12-09 | — | — | US | claimed |
| WO-2007077004-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | claimed |
| JP-2007510002-A | — | — | 2007-04-19 | — | — | JP | claimed |
| US-20070072792-A1 | Macrocyclic lactams and pharmaceutical use thereof | NOVARTIS AG (CH) | 2007-03-29 | — | — | US | claimed |
| US-20070015781-A1 | Certain substituted spirocyclic lactams and use thereof as pharmaceuticals | AUBERSON YVES | 2007-01-18 | — | — | US | claimed |
| EP-1682521-A1 | MACROCYCLIC LACTAMS AND PHARMACEUTICAL USE THEREOF | Novartis AG (CH) | 2006-07-26 | — | — | EP | claimed |
| WO-2006074950-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | claimed |
| WO-2006074940-A2 | MACROCYCLIC COMPOUNDS AND COMPOSITIONS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | claimed |
| EP-1670803-A1 | CERTAIN SUBSTITUTED SPIROCYCLIC LACTAMS AND USE THEREOF AS PHARMACEUTICALS | Novartis AG (CH) | 2006-06-21 | — | — | EP | claimed |
| WO-2005049585-A1 | MACROCYCLIC LACTAMS AND PHARMACEUTICAL USE THEREOF | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | claimed |
| WO-2005035535-A1 | CERTAIN SUBSTITUTED SPIROCYCLIC LACTAMS AND USE THEREOF AS PHARMACEUTICALS | NOVARTIS AG (CH) | 2005-04-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038943-A1 | SEROTONIN RECEPTOR MODULATOR | HTR2C, HTR2A, HTR1A | TSHR 276/4885MAOA 151/4885MAOB 90/4885 |
| US-20070072792-A1 | Macrocyclic lactams and pharmaceutical use thereof | RPS11, MRPL21, RPS4Y1 | TSHR 1165/4885MAOA 1672/4885MAOB 1066/4885 |
| US-20070015781-A1 | Certain substituted spirocyclic lactams and use thereof as pharmaceuticals | STS, RPS6KA5, RPIA | TSHR 1154/4885MAOA 2005/4885MAOB 2234/4885 |
| US-20160046574-A1 | SEROTONIN RECEPTOR MODULATORS | HTR2C, HTR2A, HTR1A | TSHR 276/4885MAOA 131/4885MAOB 78/4885 |
| US-20100311794-A1 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | HDAC1, HDAC5, HDAC3 | TSHR 4008/4885MAOA 671/4885MAOB 559/4885 |
| US-20110207714-A1 | SEROTONIN RECEPTOR MODULATORS | HTR1A, HTR2A, HTR2C | TSHR 278/4885MAOA 61/4885MAOB 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.